The impact of transrectal prostate biopsy on erectile function.

OBJECTIVE - To assess erectile function at different periods of time in patients who undergo transrectal prostate biopsy (TRPB).

METHODS - A total of 364 patients underwent TRPB. All of the patients were assessed using the International Index of Erectile Function-5 (IIEF-5).

All patients with a positive result for cancer or with previous erectile dysfunction in the initial assessment were excluded. Ninety-three patients were included and were assessed before the biopsy and at 4, 12 and 24 weeks after the TRPB, using the IIEF-5 and assessing erectile function across these time periods.

RESULTS - We assessed 93 patients. During the first prebiopsy assessment, 100% of the patients scored ≥22 points. In the first postbiopsy evaluation at 4 weeks, 66.6% scored ≥ 22 points, and 33.3% had erectile dysfunction, thereby indicating a statistically significant reduction in the IIEF-5 score (P=.001). In the second postbiopsy evaluation, only 9.1% patients still had mild to moderate erectile dysfunction (P=.04). By the end, 92.48% of the patients scored ≥ 22 points, and 7.52% still had mild erectile dysfunction, without presenting a significant difference (P=.1).

CONCLUSIONS - After a TRPB, the drop in IIEF-5 scores and the presence of erectile dysfunction are temporary and transient, with greater impairment during the first month following the procedure and improvement starting after the first month, with almost total recovery at 6 months.

Actas urologicas espanolas. 2016 Mar 28 [Epub ahead of print]

E Linden-Castro, M Pelayo-Nieto, D Espinosa-Perezgrovas, E D Rubio-Arellano, G Catalán-Quinto, F Guzmán-Hernández, J A Morales-Covarrubias, R Cortez-Betancourt

Departamento de Urología, Centro Médico Nacional 20 de Noviembre, Ciudad de México, México., Departamento de Urología, Centro Médico Nacional 20 de Noviembre, Ciudad de México, México. Departamento de Urología, Centro Médico Nacional 20 de Noviembre, Ciudad de México, México., Laboratorio de Investigación y Desarrollo Farmacéutico, Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Jalisco, Mexico., Departamento de Urología, Centro Médico Nacional 20 de Noviembre, Ciudad de México, México., Departamento de Urología, Centro Médico Nacional 20 de Noviembre, Ciudad de México, México., Departamento de Urología, Centro Médico Nacional 20 de Noviembre, Ciudad de México, México., Departamento de Urología, Centro Médico Nacional 20 de Noviembre, Ciudad de México, México.

 

 Go "Beyond the Abstract" - Read an article written by the authors for UroToday.com